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Protein kinase C was measured in the cytoskeletal fraction of lymphocytes, platelets and HL60 cells, by specific binding of PHjphorbol dibutyrate 
and by immunoblotting with antibody to a consensus equence in the regulatory domain of a-, p- and y-isozymes of protein kinase C. Treatment 
of cells for 40 min with a combination of zinc (2-50 ,eM), zinc ionophore pyrithione and unlabelled phorbol dibutyrate (200 nM) caused up to 
a ten-fold increase in cytoskeletal protein kinase C and a corresponding decrease in other cellular compartments. Omission of any of the reagents 
resulted in much less or no translocation. These effects were inhibited by l,lO-phenanthroline, which chelates zinc, and were not seen with calcium. 
Increase in cytoskeletal protein kinase C persisted for several hours and appeared to involve attachment of the enzyme to actin microfilaments. 
We propose that zinc, like calcium, regulates the distribution of PKC in cells. However, unlike calcium which controls the binding of PKC to 
the lipid component on cell membranes, zinc controls the distribution of PKC to membrane cytoskeleton, possibly actin. 
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1. INTRODUCTION 
The family of protein kinase C (PKC) enzymes plays 
a key role in normal cell activation and in the aberrant 
events leading to malignancy [ 11. PKC is regulated by 
cofactor-dependent ranslocation from cytosol to cell 
membranes. Although the cofactors (e.g. calcium) in- 
volved in the translocation to the lipid component of 
cell membranes are well known, those involved in its 
translocation to membrane-associated cytoskeleton are 
not. The cytoskeleton is a major site of action of PKC, 
where its effects may be mediated by a distinct pool of 
the enzyme [2,3]. 
Previously we reported that zinc, in the presence of 
zinc ionophores such as pyrithione and di- 
iodohydroxyquinoline, causes a large increase in the 
capacity of cells to bind a specific ligand of PKC, 
[3H]phorbol dibutyrate ([3H]PDBu) [4,5]. Here we 
demonstrate that this increase is associated with 
translocation of PKC from cytosol to a cellular 
cytoskeletal fraction. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Zinc chloride (!%Yo pure) was obtained from Merck; sodium 
pyrithione from Dr M. Whitehouse (Dept of Pathology, University of 
Adelaide, South Australia); [“H]PDBu (13 Ci/mmol) from New 
England Nuclear; unlabelled PDBu. Nonidet P-40 (NP40), A23187, 
leupeptin, phenylmethylsulphonyl fluoride (PMSF), l,lO-phen- 
anthroline (Phe) and desoxyribonuclease type I from Sigma; 1,2-sn- 
dioctanoylglycerol from Molecular Probes; sodium fluoride from 
BDH. 
2.2. Cell preparations and assays 
Human lymphocytes and platelets were prepared as described in 
[4]. HL60 cells, grown in RPM1 1640 containing 10% foetal bovine 
serum, were used two days after subculture. Stimuli (e.g. zinc, 
fluoride, unlabelled PDBu, ionophores and chelators) were added to 
cells (2 x lO’/ml) in serum free RPM1 for 40 min at 37’C. Cells were 
washed twice in phosphate buffered saline and the detergent insoluble 
cytoskeleton and soluble fraction prepared by treatment for 15 min at 
0°C with 25 mM Tris buffer (pH 8.0) containing 0.2% NP40, 30% 
sucrose, 25 mM KCl, 7.5 mM MgClz, 50~g/ml leupeptin and 1 mM 
PMSF [6]. Insoluble cytoskeletal residues were washed and 
resuspended in 25 mM Tris buffer (pH 8.0) and ultrasonicated (Bran- 
son sonifier, setting 5 for 4 x 7 s). Binding of 20 nM [“H]PDBu was 
assayed as in [4]. Soluble fractions were diluted to less than 0.01% 
NP40. before assaying [3H]PDBu binding. Scatchard analysis of 
[‘H]PDBu binding in whole cells was performed as in [5]. Actin 
microfilaments were prepared from human platelets [7], and protein 
was assayed by the Bradford method. In some experiments, the NP40 
soluble fractions and insoluble fractions from lymphocytes were col- 
lected and the proteins separated on 7.5% SDS-PAGE gels. PKC on 
these gels was then identified by immunoblotting with rabbit antibody 
to rat brain PKC (consensus equence in (Y-, & and y-isozymes) [8] as 
in [9], using ‘XI-labelled donkey anti-rabbit immunoglobulin (2000 
Ci/mmol, Amersham) as second antibody. PKC activity of different 
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fractions was assayed both by 3zP-labelling of proteins identified on 
SDS-PAGE gels [lo] and by phospho~lation of histone [I I]. 
3. RESULTS AND DISCUSSION 
Treatment of lymphocytes with 50 ,uM ZnClz in the 
presence of 20 ,QM pyrithione increased cytoskeletal- 
bound PKC twofold (Fig. la). In contrast, neither 
ZnClz pyrithione, nor CaCl2 plus or minus A23187, had 
any effect on cytoskeleton-bound PKC. In similar ex- 
periments on cell lysates or sonicates, addition of ZnClz 
without pyrithione also resulted in increased 
c~oskeleton-bound PKC (data not shown), confirming 
that in whole cells, pyrithione increases intracellular 
zinc by acting as a zinc ionophore. 
PDBu (200 nM) alone did not cause translocation of 
PKC to cytoskeleton, but it greatly facilitated the action 
of zinc. In the presence of PDBu, 50 PM ZnClz (plus 
pyrithione) caused a IO-fold increase in cytoskeletal 
PKC in lymphocytes (Fig. la). Effects of Zn were seen 
at concentrations as low as 2 $M (Fig. lb). Similarly, 
100 pug/ml 1,2-dioctanoylglycerol facilitated the effects 
of Zn (not shown). Synergy was also seen in platelets 
and HL-60 cells (not shown). Phe, a Zn chelator, in- 
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Fig. 1. Effect of Zn on t3H]PDBu binding to cytoskeleton of human 
lymphocytes. (a) Lymphocytes were either untreated (None), or 
treated with Zn (50 ,IJM ZnC12 plus 20 ,uM pyrithioine), Ca (600 ,uM 
CaC12 plus 1 yM A32187), or NaF (40 mM sodium fluoride), in the 
absence or presence of 200 nM PDBu (unlabelled) and 
1, lo-phenanthroline (Phe). (b) Synergy between Zn (l-100,~M ZnClr, 
20 PM pyrithione) and 200 nM PDBu. Values (mean f SE) pooled 
30 
Fig, 2. Immunoblot of SDS-PAGE gels, showing translocation of 80 
kDa PKC from detergent (NP40) soluble to cytoskeletal 
(NP40-insoluble) fraction of Zn-treated (SO PM ZnClr, 20 FM 
pyrithione and 200 nM PDBu) lymphocytes. Left lane contains pure 
from 7 experiments each in triplicate. rat brain PKC as marker. 
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hibited both the stim~atory effect of zinc on PKC bind- 
ing to cytoskeleton, and the facilitating effect of phor- 
bol esters (Fig. la). 
It has been proposed that Zn is an intracellular 
messenger, which is mobilized in response to certain 
stimuli, including phorbol esters [ 12-141. Fluoride, a 
potent activator of G proteins [15], caused an increase 
in lymphocyte cytoskeletal PKC, which was blocked by 
Phe (Fig. la), suggesting that Zn or another chelatable 
metal is involved. 
Immunoblotting of lymphocyte proteins separated 
on SDS-PAGE gels (Fig. 2), demonstrated that Zn 
caused a change in distribution of 80 kDa PKC from 
NP4~soluble (lipid soluble and cytosolic) to 
NP40-insoluble (cytoskeletal) fractions. This treatment 
did not change total PKC (Fig. 2, lanes 2 and 3), sug- 
gesting that Zn does not increase the synthesis of PKC. 
This gel also demonstrates that there were lower 
molecular weight immunoreactive components in the 
soluble fraction that were unaffected by Zn. These may 
be proteolytic products of PKC. It is not possible to 
assay cytoskeletal PKC by the standard catalytic assay, 
because this assay measures PKC in a soluble form. 
However, the Ca- and phospholipid-dependent 
phosphorylation of histone in the NP40-soluble frac- 
tion was decreased by pretreatment of lymphocytes 
with Zn plus PDBu, and the incorporation of 32P into 
several cytoskeletal proteins was increased (data not 
shown). 
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Fig. 3. S&chard analysis of [‘H]PDBu binding to intact Iym- 
phocytes, untreated (None) or treated with 200 nM unlabeiled PDBu 
and varying concentrations of Zn (0, 5, 10, or 50 pM ZnCl2, 20 FM 
pyrithione). Unlabelled PDBu was removed by washing cells prior to 
assay for [3H]PDBu binding. 
Translocation of PKC to cytoskeleton, characterised 
by the increase in binding of [3H]PDBu to intact cells, 
was due both to changes in binding affinity and, at 
higher concentrations of Zn, to the app~ent total 
number of binding sites (Fig. 3). This suggests that 
cytoskeletal PKC has a higher affinity for E3H]PDBu 
than lipid-soluble PKC. The very high f3HJPDBu bind- 
ing capacity of brain cells 1161 may be due to their high 
content of Zn [ 171. 
(a) 60 
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Fig. 4. (a) Persistence of cytoskeletal PKC after treatment of lym- 
phocytes with Zn (0,5, 10 or 50pM ZnClr, 20/~M pyrithione and 200 
nM PDBu) and, (b) effect of actin depolymerisation (100~g/ml deox- 
yribonuclease plus 1 mM EGTA) or 1,IO-phenanthroline (Phe) on 
f3H]PDBu binding activity of cytoskeleton, isolated foliowing treat- 
ment with Zn (50 FM ZnCi;i, 50 pM pyrithione, 200 nM PD3n). 
Values are mean + SB (n = 3). 
Fig. 4 shows that cehular f3HfPD3u binding remain- 
ed elevated for at least 7 h after treatment of cells with 
Zn plus PDBu, indicating that PKC translocated to the 
cytoskeleton remains bound for some time, particularly 
in comparison to Ca-dependent membrane-bound PKC 
which undergoes rapid turnover [l]. An example of 
where Zn may have a function in sustained cellular 
responses involving PKC is in the long-term potentia- 
tion of synaptic trans~ssion in the hippoc~pus 1181, 
where Zn, released into synapses of excited hippo~am- 
pal neurons, reaches &on~entratio~s of up to 200 FM 
U41* 
Previous immuno~~o~hemic~ studies have shown 
that in fibroblasts, PKC is associated with actin 
filaments [3], and suggest hat the cytoskeleton compo- 
nent to which PKC binds may be actin. This was tested 
using platelets since actin microfilaments are readily 
prepared from these cells [7]. Platelets were treated with 
50,~M ZnC12 (plus 20&M pyrithione and 200 nM PDBu) 
for 40 min, before isolation of actin ~~rof~~ents. 
These microfil~ents had a 77% increase in 13~]PDBu 
binding over ~i~rofil~ents from control cells (Fig. 
4b). Furthermore, treatment of the lymphocyte cyto- 
skeleton with 100 pug/ml desoxyribonuclease I plus 1 
mM EGTA, which de-polymerises actin 1191, caused a 
60% reduction in [3H]PDBu binding (Fig. 4b). These 
results suggest hat Zn causes PKC to translocate to 
polymerised actin components of the cytoskeleton. Phe 
treatment of the microfilaments did not reduce the 
[‘H]PDBu binding (Fig. 4b), suggesting that neither 
zinc nor other metals are required to maintain the PKC- 
actin complex. 
Whether or not Zn interacts directly with PKC is not 
known. However, the cysteine-rich motifs in the 
regulatory domain of PKC are similar to the Zn- 
binding ‘finger motifs’ of steroid receptors, and are 
essential for 13H]PDBu binding [20]. This type of motif 
also appears to be involved in other types of Zn- 
dependent protein-protein interactions [Zl]. 
We propose that membrane PKC exists in at least two 
states, one in association with phospholipid and Ca, 
and the other with phospholipid, Zn and cytoskeletal 
protein, possibly polymerised actin. The kinetics of the 
formation of the ~~oske~etaI-PKC complex and its ef- 
fects on PKC specificity and activity are now being in- 
vestigated in our laboratoryy. 
~c~~o~~e~ge~e~~~~ This research was supported by the National 
Health and Medical Research Council of Australia, the Anti-Cancer 
Foundation of South Australia, and a major research grant from the 
University of Adelaide. 
REFERENCES 
fl] Nishizuka, Y. fI988) Nature 334,661-665. 
[2] Papadopolous, Y. and Hall, P.F. (1989) J. Cell Biof. 308, 
553-567. 
133 










Jaken, S., Leach, K. and Klauck, T. (1989) J. Cell Biol. 109, 
697-704. 
Forbes, I.J., Zalewski, P.D., Hurst, N.P., Giannakis, C. and 
Whitehouse, M.W. (1989) FBBS Lett. 247, 445-447. 
Forbes, I.J., Zalewski, P.D., Giannakis, C., Petkoff, H.S. and 
Cowled, P.A (1990) Biochim. Biophys. Acta (in press). 
Chen, Z.Z., Coggeshall, L.M. and Cambier, J.C. (1987) J. Im- 
munol. 136, 2360-2364. 
Rosenberg, S., Stracher, A. and Lucas, R.C. (1981) J. Cell Biol. 
91, 201-211. 
Testori, A., Hill, C.S.T., Fournier, A., Burgoyne, L.A. and 
Murray, A.W. (1988) Biochem. Biophys. Res. Commun. 156, 
222-227. 
Fournier, A., Hardy, S.J., Clark, R.J. and Murray, A.W. 
(1989) B&hem. Biophys. Res. Commun. 161, 556-561. 
Hurst, N.P., Gorjatschko, L., Betts, W.H., Zalewski, P.D. and 
Forbes, I.J. (1989) Rheumatol. Int. 8, 245-250. 
Tapley, P.M. and Murray, A.W. (1984) Biochem. Biophys. Res. 









Lw Ono, Y., Fujii, T., Igarishi, K., Kuno, T., Tanaka, C., Kik- 
kawa, U. and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. USA 
86, 4868-487 1. 
Pll Frankel, A.D. and Pabo, C.O. (1988) Cell 53, 675-676. 
Grummt, F., Weinmann-Dorsch, C., Schneider-Schaulies, J. 
and Lux, A. (1986) Exp. Cell Res. 163, 191-200. 
Csermely, P., Gueth, S. and Somogyi, J. (1987) Carcinogenesis 
8, 1663-1666. 
Assaf, S.Y. and Chung, S.-H. (1984) Nature 308, 734-736. 
Stmad, C.F. and Wong, K. (1985) Biochem. Biophys. Res. 
Commun. 133, 161-167. 
Blumberg, P.M., Jaken, S., Konig, B., Sharkey, N.A., Leach, 
K.L., Jeng, A.Y. and Yen, H. (1984) Biochem. Pharmacol. 33, 
933-940. 
Danscher, G., Shipley, M.T. and Andersen, P. (1976) Brain Res. 
85, 522-526. 
Akers, R.F., Lovinger, D.M., Collery, P.A., Linden, D.J. and 
Touttenberg, A. (1986) Science 231, 587-589. 
Woda, B.A. and Woodin, M.B. (1984) J. Immunol. 133, 
2767-2772. 
134 
